Leerink Partnrs Weighs in on Kura Oncology Q1 Earnings

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Kura Oncology in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst J. Chang anticipates that the company will post earnings per share of $0.15 for the quarter. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology's FY2025 earnings at $0.15 EPS.

Several other equities analysts have also recently issued reports on the company. Jefferies Financial Group reduced their price objective on Kura Oncology from $32.00 to $28.00 and set a "buy" rating for the company in a report on Thursday, November 21st. BTIG Research downgraded Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. HC Wainwright boosted their price target on Kura Oncology from $37.00 to $40.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Bank of America decreased their target price on Kura Oncology from $36.00 to $29.00 and set a "buy" rating for the company in a research report on Friday, November 22nd. Finally, TD Cowen reaffirmed a "buy" rating on shares of Kura Oncology in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $27.13.

Kura Oncology Price Performance

Shares of KURA traded down $0.07 during mid-day trading on Monday, hitting $8.28. The company's stock had a trading volume of 699,131 shares, compared to its average volume of 1,823,542. The firm has a 50-day simple moving average of $8.58 and a 200 day simple moving average of $14.73. The firm has a market capitalization of $643.85 million, a P/E ratio of -3.51 and a beta of 0.78. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new position in shares of Kura Oncology during the 4th quarter valued at $8,265,000. Jump Financial LLC boosted its stake in Kura Oncology by 862.0% during the fourth quarter. Jump Financial LLC now owns 239,933 shares of the company's stock valued at $2,090,000 after buying an additional 214,993 shares in the last quarter. XTX Topco Ltd acquired a new position in Kura Oncology during the fourth quarter worth about $180,000. Barclays PLC raised its position in Kura Oncology by 22.0% in the fourth quarter. Barclays PLC now owns 201,864 shares of the company's stock worth $1,757,000 after acquiring an additional 36,380 shares in the last quarter. Finally, Optimize Financial Inc acquired a new stake in Kura Oncology in the 4th quarter valued at about $100,000.

Insider Buying and Selling at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares of the company's stock, valued at $694,551.11. This represents a 5.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares of the company's stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,255 shares of company stock worth $100,739 over the last quarter. 5.50% of the stock is owned by corporate insiders.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.